(Q35017613)

5 August 2017

0 references

Hepatotoxicity induced by trastuzumab used for breast cancer adjuvant therapy: a case report (English)

1 reference

5 August 2017

1 reference

1 reference

Kazuo Ishizuna

1

1 reference

5 August 2017

Jun Ninomiya

series ordinal

2

1 reference

5 August 2017

Toshihisa Ogawa

series ordinal

3

1 reference

5 August 2017

Eiichi Tsuji

series ordinal

4

1 reference

5 August 2017

language of work or name

English

0 references

publication date

10 December 2014

1 reference

Journal of Medical Case Reports

5 August 2017

published in

1 reference

5 August 2017

volume

8

1 reference

5 August 2017

page(s)

417

1 reference

Trastuzumab-induced hepatotoxicity: a case report

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307619

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307619

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307619

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307619

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307619

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307619

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307619

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307619

Trastuzumab-induced hepatotoxicity

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1752-1947-8-417

Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25491149

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Reversible liver toxicity with adjuvant trastuzumab for localized breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25491149

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1752-1947-8-417

1 reference

5 August 2017

1 reference

5 August 2017

1 reference